Tech Company Financing Transactions

Endeavor BioMedicines Funding Round

Matrix Capital Management, Abrdn and Ally Bridge Group invested in a $132.5 million Series C funding round for Endeavor BioMedicines. The round was announced on 4/24/2024.

Transaction Overview

Announced On
4/24/2024
Transaction Type
Venture Equity
Amount
$132,500,000
Round
Series C
Proceeds Purpose
The company will use the financing proceeds to advance the clinical development of ENV-101, its lead candidate for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF); and to advance ENV-501, a human epidermal growth factor 3 (HER3) antibody-drug conjugate (ADC) for the treatment of HER3-positive solid tumors through clinical proof-of-concept studies.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
514 Via de la Valle 203
Solana Beach, CA 92075
USA
Email Address
Overview
Endeavor BioMedicines is developing new treatments targeting the underlying causes of pulmonary fibrosis. The company is developing taladegib, a small-molecule inhibitor of the Hedgehog signaling pathway, that is being investigated for the treatment of idiopathic pulmonary fibrosis (IPF).
Profile
Endeavor BioMedicines LinkedIn Company Profile
Social Media
Endeavor BioMedicines Company Twitter Account
Company News
Endeavor BioMedicines News
Facebook
Endeavor BioMedicines on Facebook
YouTube
Endeavor BioMedicines on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
John Hood
  John Hood LinkedIn Profile  John Hood Twitter Account  John Hood News  John Hood on Facebook
Chief Financial Officer
Raghu Saripalli
  Raghu Saripalli LinkedIn Profile  Raghu Saripalli Twitter Account  Raghu Saripalli News  Raghu Saripalli on Facebook
Chief Scientific Officer
Miguel De Los Rios
  Miguel De Los Rios LinkedIn Profile  Miguel De Los Rios Twitter Account  Miguel De Los Rios News  Miguel De Los Rios on Facebook


 

 

Browse more venture capital transactions:

Prev: 4/24/2024: Dripos venture capital transaction
Next: 4/24/2024: Parloa venture capital transaction

 

Share this article

 


About Our Venture Capital Transactions Database

We do our best to record tech company VC transactions. VC investment data records on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary